Prostate cancer
Conditions
Interventions
RS-RARP:Retzius-sparing robotic assisted prostatectomy
RARP:Conventional robotic assisted prostatectomy
Sponsors
Department of Urology, The Affiliated Drum Tower Hospital, Medical School of Nanjing University
Eligibility
Sex/Gender
Male
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Males aged 18 to 75 years; (2) Patients who have been diagnosed as prostate cancer; (3) ECOG score =1; Expected lifetime >10 yrs; (4) Patients who are voluntary to join in the trial.;Inclusion criteria: (1) Males aged 18 to 75 years; (2) Patients who have been diagnosed as prostate cancer; (3) ECOG score =1; Expected lifetime >10 yrs; (4) Patients who are voluntary to join in the trial.;Inclusion criteria: (1) Males aged 18 to 75 years; (2) Patients who have been diagnosed as prostate cancer; (3) ECOG score =1; Expected lifetime >10 yrs; (4) Patients who are voluntary to join in the trial.;Inclusion criteria: (1) Males aged 18 to 75 years; (2) Patients who have been diagnosed as prostate cancer; (3) ECOG score =1; Expected lifetime >10 yrs; (4) Patients who are voluntary to join in the trial.;Inclusion criteria: (1) Males aged 18 to 75 years; (2) Patients who have been diagnosed as prostate cancer; (3) ECOG score =1; Expected lifetime >10 yrs; (4) Patients who are voluntary to join in the trial.
Exclusion criteria
Exclusion criteria: (1) Neuroendocrine prostate cancer including small cell carcinoma; (2) Metastastic prostate cancer; (3) Locally advanced prostate cancer; (4) Patients with prostate volume more than 100 ml; (5) Patients with mental illness; (6) Patients who have undergone pelvic radiotherapy or surgery.;Exclusion criteria: (1) Neuroendocrine prostate cancer including small cell carcinoma; (2) Metastastic prostate cancer; (3) Locally advanced prostate cancer; (4) Patients with prostate volume more than 100 ml; (5) Patients with mental illness; (6) Patients who have undergone pelvic radiotherapy or surgery.;Exclusion criteria: (1) Neuroendocrine prostate cancer including small cell carcinoma; (2) Metastastic prostate cancer; (3) Locally advanced prostate cancer; (4) Patients with prostate volume more than 100 ml; (5) Patients with mental illness; (6) Patients who have undergone pelvic radiotherapy or surgery.;Exclusion criteria: (1) Neuroendocrine prostate cancer including small cell carcinoma; (2) Metastastic prostate cancer; (3) Locally advanced prostate cancer; (4) Patients with prostate volume more than 100 ml; (5) Patients with mental illness; (6) Patients who have undergone pelvic radiotherapy or surgery.;Exclusion criteria: (1) Neuroendocrine prostate cancer including small cell carcinoma; (2) Metastastic prostate cancer; (3) Locally advanced prostate cancer; (4) Patients with prostate volume more than 100 ml; (5) Patients with mental illness; (6) Patients who have undergone pelvic radiotherapy or surgery.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Continence; | — |
Secondary
| Measure | Time frame |
|---|---|
| Positive surgical margin;Biochemical recurrence;Erectile function;Blood loss;Drainage;Hospitalization time; | — |
Countries
China
Contacts
Public ContactHongqian Guo;Hongqian Guo;Hongqian Guo;Hongqian Guo;Hongqian Guo ;;;;
The Affiliated Drum Tower Hospital, Medical School of Nanjiing University;The Affiliated Drum Tower Hospital, Medical School of Nanjiing University;The Affiliated Drum Tower Hospital, Medical School of Nanjiing University;The Affiliated Drum Tower Hospital, Medical School of Nanjiing University;The Affiliated Drum Tower Hospital, Medical School of Nanjiing University
Outcome results
None listed